Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
VHAG in Treating R/R T-ALL/LBL
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT06742463
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Asparaginase Erwinia chrysanthemiProcedure: Biospecimen CollectionProcedure: Bone Marrow CollectionProcedure: Computed TomographyDrug: CyclophosphamideDrug: DoxorubicinDrug: EtoposideBiological: FilgrastimBiological: PegfilgrastimProcedure: Positron Emission TomographyDrug: PrednisoneBiological: RituximabDrug: Vincristine
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 30
- Registration Number
- NCT06738368
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- David S Shulman, MD
- Target Recruit Count
- 63
- Registration Number
- NCT06709495
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT06547112
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06528691
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 99
- Registration Number
- NCT06520163
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Lishui Central Hospital, Lishui, Zhejiang, China
🇨🇳Dongyang People's Hospital, Dongyang, Zhejiang, China
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 99
- Registration Number
- NCT06520176
- Locations
- 🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳The First Hospital of Jiaxing, Jiaxing, Zhejiang, China
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 81
- Registration Number
- NCT06361329
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 10
- Registration Number
- NCT06325709
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 378
- Registration Number
- NCT06212752
- Locations
- 🇯🇵
Miyagi Cancer Center ( Site 4401), Natori, Miyagi, Japan
🇯🇵Fujita Health University ( Site 4406), Toyoake, Aichi, Japan
🇯🇵Kurume University Hospital ( Site 4412), Kurume, Fukuoka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.